NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 17, 2021 | Series C | $80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | — | Series C |